Abstract
Emicizumab is a novel monoclonal antibody approved for the prevention and treatment of bleeds in patients with hemophilia A with or without inhibitors. The development of inhibitors, which are neutralizing antibodies to clotting factor replacement therapy, is a major treatment-related complication in hemophilia management. In patients with inhibitors, bleed prophylaxis using emicizumab has been shown to be cost-effective compared to prophylaxis using bypassing agents – with supporting evidence for its reimbursement in this population in Canada.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
